Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer.
about
Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.Novel translational strategies in colorectal cancer research.Stem memory T cells (TSCM)-their role in cancer and HIV immunotherapiesArchaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses.Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growthSynergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in miceClinical opportunities in combining immunotherapy with radiation therapy.Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses.Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma.Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy.Systemic therapy for advanced hepatocellular carcinoma: past, present, and future.The confluence of stereotactic ablative radiotherapy and tumor immunology.The promise of combining radiation therapy and immunotherapy: morbidity and toxicity.MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.Genotoxic and cytotoxic activity of host defense peptides against human soft tissue sarcoma in an in vitro model.Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy.Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2(180-188)-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-γ-dependent manner: application of Trp2(180-188) peptides.The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up
P2860
Q33509292-36B267EB-6342-4123-A285-F71BAC18C2B0Q33653210-9790F680-301E-4828-A4B3-7204BFA1AD72Q34382804-2D211BDC-53A8-4466-87B4-DE7579ACA309Q34511615-B7C62ADC-199D-4673-8AF8-038F3AE79685Q34557185-94C1BD5F-45C5-4136-B151-9C18593F32F8Q34757266-F3EAE173-E068-4422-90B1-6B33A4A6A3FFQ36038477-DCD4D7DF-A575-489D-B1F6-0C2833586346Q36402501-A182F848-5F2C-4CEE-A319-60AEFA34AB80Q36403509-B3BE8D79-4D83-4552-8A09-7462F5DF5FC5Q36449873-67026058-C24E-42C7-8206-79760B3B49AFQ36642808-4F373ECC-15D4-412B-937A-F23A20353E18Q37375286-B0252F98-4531-4174-A894-58C30176449EQ37734194-7B469E63-B94C-4125-9350-A04F230A0A31Q37734197-A1600B62-C7ED-4E14-8026-B4D2A903F3D9Q37967688-9FB79691-AF75-4ACD-A86E-A9566E29DC73Q39071019-1081B996-C8A8-4D7E-A95D-33046DAD5738Q39290133-152822D3-326A-41C2-BCE9-F30CC814889EQ39488599-8DD962E0-88DF-4EB2-8F3F-1D7E718DFB30Q39564978-F8263A5A-E490-46D7-8E7B-661C86BFC58FQ39627913-26F090C4-357F-49C9-94B6-3CEB6895ED10Q50964057-8F503C75-0247-4851-BBAC-7CF1591605EBQ58690844-B40196DD-DE9A-4DEA-89F9-EC969745AEB9
P2860
Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Bedside to bench and back agai ...... ew immunotherapies for cancer.
@ast
Bedside to bench and back agai ...... ew immunotherapies for cancer.
@en
Bedside to bench and back agai ...... ew immunotherapies for cancer.
@nl
type
label
Bedside to bench and back agai ...... ew immunotherapies for cancer.
@ast
Bedside to bench and back agai ...... ew immunotherapies for cancer.
@en
Bedside to bench and back agai ...... ew immunotherapies for cancer.
@nl
prefLabel
Bedside to bench and back agai ...... ew immunotherapies for cancer.
@ast
Bedside to bench and back agai ...... ew immunotherapies for cancer.
@en
Bedside to bench and back agai ...... ew immunotherapies for cancer.
@nl
P2093
P2860
P356
P1476
Bedside to bench and back agai ...... ew immunotherapies for cancer.
@en
P2093
Christian S Hinrichs
Christopher A Klebanoff
Claudia Wrzesiniski
David M Heimann
Deborah R Surman
Leroy N Hwang
Luca Gattinoni
Nicholas P Restifo
Paul A Antony
Paul J Spiess
P2860
P304
P356
10.1189/JLB.0304120
P577
2004-05-20T00:00:00Z